

## 94TH GENERAL ASSEMBLY State of Illinois 2005 and 2006 SB2432

Introduced 1/18/2006, by Sen. John J. Cullerton

## SYNOPSIS AS INTRODUCED:

305 ILCS 5/5-5.12

from Ch. 23, par. 5-5.12

Amends the Illinois Public Aid Code. In provisions concerning the Medicaid program, provides that the Department of Healthcare and Family Services may not impose requirements for prior approval based on a preferred drug list for anti-retroviral, anti-hemophilic factor concentrates, or any atypical antipsychotics, conventional antipsychotics, or anticonvulsants used for the treatment of serious mental illnesses (instead of providing that the Department may not impose such requirements until 30 days after it has conducted a study of the impact of such requirements on patient care and submitted a report to the Speaker of the House of Representatives and the President of the Senate). Effective immediately.

LRB094 15366 DRJ 50557 b

FISCAL NOTE ACT MAY APPLY

2

3

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

1 AN ACT concerning public aid.

## Be it enacted by the People of the State of Illinois, represented in the General Assembly:

- Section 5. The Illinois Public Aid Code is amended by changing Section 5-5.12 as follows:
- 6 (305 ILCS 5/5-5.12) (from Ch. 23, par. 5-5.12)
- 7 Sec. 5-5.12. Pharmacy payments.
  - (a) Every request submitted by a pharmacy for reimbursement under this Article for prescription drugs provided to a recipient of aid under this Article shall include the name of the prescriber or an acceptable identification number as established by the Department.
  - (b) Pharmacies providing prescription drugs under this Article shall be reimbursed at a rate which shall include a professional dispensing fee as determined by the Illinois Department, plus the current acquisition cost of the prescription drug dispensed. The Illinois Department shall update its information on the acquisition costs of all prescription drugs no less frequently than every 30 days. However, the Illinois Department may set the rate of reimbursement for the acquisition cost, by rule, at a percentage of the current average wholesale acquisition cost.
- 23 (c) (Blank).
- (d) The Department shall not impose requirements for prior 24 25 approval based on a preferred drug list for anti-retroviral, 26 anti-hemophilic factor concentrates, or any atypical 27 antipsychotics, conventional antipsychotics, 28 anticonvulsants used for the treatment of serious mental illnesses until 30 days after it has conducted a study of the 29 30 impact of such requirements on patient care and submitted a report to the Speaker of the House of Representatives and the 31 President of the Senate. 32

- 1 (Source: P.A. 93-106, eff. 7-8-03; 94-48, eff. 7-1-05.)
- 2 Section 99. Effective date. This Act takes effect upon
- 3 becoming law.